Sign in

ABBOTT LABORATORIES

ABT

Share price not shown yet: live market data is not connected. Everything below comes from ABT’s own SEC filings.

View options chain →

Fundamentals

SEC filings

A newer quarter has been reported. 10-Q filed Jul 28, 2026 for the period ending Jun 30, 2026, but the SEC has not published its structured XBRL data yet, so the charts below end one period earlier. We re-check every few hours and the quarter appears automatically once the SEC releases it.

Ratios that need a share price (P/E, PEG, P/S, dividend yield) are not shown yet, because live market data is not connected. Everything below comes from filed financials.

Rule of 40
23%
rev growth + FCF margin
Revenue growth
+6.6%
TTM vs prior TTM
FCF margin
16.3%
ROE (TTM)
12.4%
TTM NI ÷ avg equity
Net debt
$26.8B
total debt − cash & ST inv.
Dilution (YoY)
+0.1%
negative = buybacks
SBC / revenue
1.5%
TTM revenue
$45.1B

Revenue

$0B$2B$4B$6B$8B$10B$12BSep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$11B

EPS (diluted)

$0.00$1.00$2.00$3.00$4.00$5.00Sep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$0.61

Operating

15%20%25%Sep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’2612%

Net income

$0B$2B$4B$6B$8BSep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$1B

Net margin

20%40%60%80%Sep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’2610%

Free cash flow vs. stock-based comp

FCFSBC
$0.0B$0.5B$1.0B$1.5B$2.0B$2.5BSep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$0.9B

Operating cash flow vs. capex

OCFCapex
$0B$1B$2B$3BSep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$1B

R&D vs. SG&A

R&DSG&A
$0B$1B$2B$3B$4BSep ’21Jun ’22Mar ’23Dec ’23Sep ’24Jun ’25Mar ’26$1B

Insider activity

SEC Form 4
Reading Form 4 filings from SEC EDGAR…